Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Pharmacokinetic and Tolerability of Alirocumab SAR236553 (REGN727) in Patients With Hepatic Impairment and in Healthy Subjects

This study has been completed.
Regeneron Pharmaceuticals
Information provided by (Responsible Party):
Sanofi Identifier:
First received: August 16, 2012
Last updated: June 27, 2013
Last verified: June 2013
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: May 2013
  Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)